Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 24829758)


Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses.

Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL.

J Immunother Cancer. 2014 Jan 27;2:1. doi: 10.1186/2051-1426-2-1. eCollection 2014.


Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH.

Neoplasia. 2012 Dec;14(12):1115-21.


Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.

Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA.

J Immunother. 2004 May-Jun;27(3):240-53.


Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH.

PLoS Med. 2007 Dec;4(12):e353.


Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.

Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, Oksanen M, Kairemo K, Joensuu T, Kanerva A, Hemminki A.

Oncoimmunology. 2015 Apr 2;4(3):e989771. eCollection 2015 Mar.


Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Hörig H, Marincola FM.

J Clin Invest. 2005 Jul;115(7):1903-12. Epub 2005 Jun 2.


Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.

Reinboth J, Ascierto ML, Chen NG, Zhang Q, Yu YA, Aguilar RJ, Carretero R, Worschech A, Zhao Y, Wang E, Marincola FM, Szalay AA.

Hum Gene Ther Methods. 2012 Oct;23(5):285-96. doi: 10.1089/hgtb.2012.057. Epub 2012 Nov 6.


Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.

Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA.

J Immunother. 1997 Jan;20(1):38-47.


Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.

Ehrig K, Kilinc MO, Chen NG, Stritzker J, Buckel L, Zhang Q, Szalay AA.

J Transl Med. 2013 Mar 26;11:79. doi: 10.1186/1479-5876-11-79.


Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.

Sivanandham M, Shaw P, Bernik SF, Paoletti E, Wallack MK.

Cancer Immunol Immunother. 1998 Jul;46(5):261-7.


Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.

Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE 3rd.

Clin Cancer Res. 2006 Oct 1;12(19):5850-8.


Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.

Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P, Acres B.

J Immunother. 2000 Sep-Oct;23(5):570-80.


Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.

Feder-Mengus C, Schultz-Thater E, Oertli D, Marti WR, Heberer M, Spagnoli GC, Zajac P.

Hum Gene Ther. 2005 Mar;16(3):348-60.


Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.

Adamina M, Weber WP, Rosenthal R, Schumacher R, Zajac P, Guller U, Frey DM, Oertli D, Zuber M, Heberer M, Spagnoli GC.

Contemp Clin Trials. 2008 Mar;29(2):165-81. Epub 2007 Jul 17.


Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.

Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, Adamina M, Schumacher R, Harder F, Heberer M, Spagnoli GC.

Hum Gene Ther. 2002 Mar 1;13(4):569-75.


Design and testing of novel oncolytic vaccinia strains.

Thorne SH.

Methods Mol Biol. 2009;542:635-47. doi: 10.1007/978-1-59745-561-9_32.


Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus.

Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, Carpenter SG, Carson J, Au J, Mittra A, Gonen M, Zanzonico PB, Fong Y, Szalay AA.

J Transl Med. 2011 Mar 31;9:36. doi: 10.1186/1479-5876-9-36.


The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Thorne SH, Bartlett DL, Kirn DH.

Curr Gene Ther. 2005 Aug;5(4):429-43. Review.


Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, Park BH, Kirn DH, Hwang TH.

Sci Transl Med. 2013 May 15;5(185):185ra63. doi: 10.1126/scitranslmed.3005361.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk